Christoph Wanner1, Hiddo J L Heerspink2, Bernard Zinman3, Silvio E Inzucchi4, Audrey Koitka-Weber5,6,7, Michaela Mattheus6, Stefan Hantel8, Hans-Juergen Woerle9, Uli C Broedl6, Maximilian von Eynatten6, Per-Henrik Groop7,10,11,12. 1. Division of Nephrology, Department of Medicine, Würzburg University Clinic, Würzburg, Germany; Wanner_C@ukw.de. 2. Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. 3. Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada. 4. Section of Endocrinology, Yale University School of Medicine, New Haven, Connecticut. 5. Division of Nephrology, Department of Medicine, Würzburg University Clinic, Würzburg, Germany. 6. Boehringer Ingelheim International GmbH, Ingelheim, Germany. 7. Department of Diabetes, Central Clinical School, Monash University, Melbourne, Victoria, Australia. 8. Boehringer Ingelheim International GmbH, Biberach, Germany. 9. Ulm University, Ulm, Germany. 10. Folkhälsan Institute of Genetics, Folkhälsan Research Center, Helsinki, Finland. 11. Abdominal Centre Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; and. 12. Research Programs Unit, Diabetes and Obesity, University of Helsinki, Helsinki, Finland.
Abstract
BACKGROUND:Empagliflozin slowed the progression of CKD in patients with type 2 diabetes and cardiovascular disease in the EMPA-REG OUTCOME Trial. In a prespecified statistical approach, we assessed treatment differences in kidney function by analyzing slopes of eGFR changes. METHODS: Participants (n=7020) were randomized (1:1:1) to empagliflozin 10 mg/d, empagliflozin 25 mg/d, or placebo added to standard of care. We calculated eGFR slopes using random-intercept/random-coefficient models for prespecified study periods: treatment initiation (baseline to week 4), chronic maintenance treatment (week 4 to last value on treatment), and post-treatment (last value on treatment to follow-up). RESULTS: Compared with placebo, empagliflozin was associated with uniform shifts in individual eGFR slopes across all periods. On treatment initiation, adjusted mean slope (eGFR change per week, ml/min per 1.73 m2) decreased with empagliflozin (-0.77; 95% confidence interval, -0.83 to -0.71; placebo: 0.01; 95% confidence interval, -0.08 to 0.10; P<0.001). However, annual mean slope (ml/min per 1.73 m2 per year) did not decline with empagliflozin during chronic treatment (empagliflozin: 0.23; 95% confidence interval, 0.05 to 0.40; placebo: -1.46; 95% confidence interval, -1.74 to -1.17; P<0.001). After drug cessation, the adjusted mean eGFR slope (ml/min per 1.73 m2 per week) increased and mean eGFR returned toward baseline level only in the empagliflozin group (0.56; 95% confidence interval, 0.49 to 0.62; placebo -0.02; 95% confidence interval, -0.12 to 0.08; P<0.001). Results were consistent across patient subgroups at higher CKD risk. CONCLUSIONS: The hemodynamic effects of empagliflozin, associated with reduction in intraglomerular pressure, may contribute to long-term preservation of kidney function.
RCT Entities:
BACKGROUND:Empagliflozin slowed the progression of CKD in patients with type 2 diabetes and cardiovascular disease in the EMPA-REG OUTCOME Trial. In a prespecified statistical approach, we assessed treatment differences in kidney function by analyzing slopes of eGFR changes. METHODS:Participants (n=7020) were randomized (1:1:1) to empagliflozin 10 mg/d, empagliflozin 25 mg/d, or placebo added to standard of care. We calculated eGFR slopes using random-intercept/random-coefficient models for prespecified study periods: treatment initiation (baseline to week 4), chronic maintenance treatment (week 4 to last value on treatment), and post-treatment (last value on treatment to follow-up). RESULTS: Compared with placebo, empagliflozin was associated with uniform shifts in individual eGFR slopes across all periods. On treatment initiation, adjusted mean slope (eGFR change per week, ml/min per 1.73 m2) decreased with empagliflozin (-0.77; 95% confidence interval, -0.83 to -0.71; placebo: 0.01; 95% confidence interval, -0.08 to 0.10; P<0.001). However, annual mean slope (ml/min per 1.73 m2 per year) did not decline with empagliflozin during chronic treatment (empagliflozin: 0.23; 95% confidence interval, 0.05 to 0.40; placebo: -1.46; 95% confidence interval, -1.74 to -1.17; P<0.001). After drug cessation, the adjusted mean eGFR slope (ml/min per 1.73 m2 per week) increased and mean eGFR returned toward baseline level only in the empagliflozin group (0.56; 95% confidence interval, 0.49 to 0.62; placebo -0.02; 95% confidence interval, -0.12 to 0.08; P<0.001). Results were consistent across patient subgroups at higher CKD risk. CONCLUSIONS: The hemodynamic effects of empagliflozin, associated with reduction in intraglomerular pressure, may contribute to long-term preservation of kidney function.
Authors: Lennart Tonneijck; Marcel H A Muskiet; Mark M Smits; Erik J van Bommel; Hiddo J L Heerspink; Daniël H van Raalte; Jaap A Joles Journal: J Am Soc Nephrol Date: 2017-01-31 Impact factor: 10.121
Authors: Hiddo J L Heerspink; Bruce A Perkins; David H Fitchett; Mansoor Husain; David Z I Cherney Journal: Circulation Date: 2016-07-28 Impact factor: 29.690
Authors: David Z I Cherney; Bruce A Perkins; Nima Soleymanlou; Maria Maione; Vesta Lai; Alana Lee; Nora M Fagan; Hans J Woerle; Odd Erik Johansen; Uli C Broedl; Maximilian von Eynatten Journal: Circulation Date: 2013-12-13 Impact factor: 29.690
Authors: Meg J Jardine; Kenneth W Mahaffey; Bruce Neal; Rajiv Agarwal; George L Bakris; Barry M Brenner; Scott Bull; Christopher P Cannon; David M Charytan; Dick de Zeeuw; Robert Edwards; Tom Greene; Hiddo J L Heerspink; Adeera Levin; Carol Pollock; David C Wheeler; John Xie; Hong Zhang; Bernard Zinman; Mehul Desai; Vlado Perkovic Journal: Am J Nephrol Date: 2017-12-13 Impact factor: 3.754
Authors: T Heise; E Seewaldt-Becker; S Macha; S Hantel; S Pinnetti; L Seman; H J Woerle Journal: Diabetes Obes Metab Date: 2013-02-17 Impact factor: 6.577
Authors: Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh Journal: Ann Intern Med Date: 2009-05-05 Impact factor: 25.391
Authors: Dorothea Nitsch; Morgan Grams; Yingying Sang; Corri Black; Massimo Cirillo; Ognjenka Djurdjev; Kunitoshi Iseki; Simerjot K Jassal; Heejin Kimm; Florian Kronenberg; Cecilia M Oien; Andrew S Levey; Adeera Levin; Mark Woodward; Brenda R Hemmelgarn Journal: BMJ Date: 2013-01-29
Authors: Bernard Zinman; Silvio E Inzucchi; John M Lachin; Christoph Wanner; Roberto Ferrari; David Fitchett; Erich Bluhmki; Stefan Hantel; Joan Kempthorne-Rawson; Jennifer Newman; Odd Erik Johansen; Hans-Juergen Woerle; Uli C Broedl Journal: Cardiovasc Diabetol Date: 2014-06-19 Impact factor: 9.951
Authors: Brendon L Neuen; Toshiaki Ohkuma; Bruce Neal; David R Matthews; Dick de Zeeuw; Kenneth W Mahaffey; Greg Fulcher; Qiang Li; Meg Jardine; Richard Oh; Hiddo L Heerspink; Vlado Perkovic Journal: J Am Soc Nephrol Date: 2019-09-17 Impact factor: 10.121
Authors: Glenn M Chertow; Pablo E Pergola; Fang Chen; Brian J Kirby; John S Sundy; Uptal D Patel Journal: J Am Soc Nephrol Date: 2019-09-10 Impact factor: 10.121
Authors: Matthew Griffin; Veena S Rao; Juan Ivey-Miranda; James Fleming; Devin Mahoney; Christopher Maulion; Nisha Suda; Krishmita Siwakoti; Tariq Ahmad; Daniel Jacoby; Ralph Riello; Lavanya Bellumkonda; Zachary Cox; Sean Collins; Sangchoon Jeon; Jeffrey M Turner; F Perry Wilson; Javed Butler; Silvio E Inzucchi; Jeffrey M Testani Journal: Circulation Date: 2020-05-15 Impact factor: 29.690
Authors: Adeera Levin; Vlado Perkovic; David C Wheeler; Stefan Hantel; Jyothis T George; Maximilian von Eynatten; Audrey Koitka-Weber; Christoph Wanner Journal: Clin J Am Soc Nephrol Date: 2020-09-29 Impact factor: 8.237